Laboratory Co. of America Holdings (NYSE:LH) Director Kerrii B. Anderson Sells 1,000 Shares

Laboratory Co. of America Holdings (NYSE:LH - Get Free Report) Director Kerrii B. Anderson sold 1,000 shares of the stock in a transaction dated Thursday, October 24th. The stock was sold at an average price of $230.00, for a total transaction of $230,000.00. Following the completion of the sale, the director now directly owns 13,722 shares in the company, valued at approximately $3,156,060. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Laboratory Co. of America Stock Down 0.6 %

LH traded down $1.44 during trading hours on Friday, hitting $228.63. 819,192 shares of the company's stock were exchanged, compared to its average volume of 668,948. Laboratory Co. of America Holdings has a 12-month low of $191.97 and a 12-month high of $239.50. The firm has a market cap of $19.20 billion, a P/E ratio of 43.11, a price-to-earnings-growth ratio of 1.70 and a beta of 1.05. The company has a current ratio of 0.88, a quick ratio of 0.77 and a debt-to-equity ratio of 0.39. The firm has a 50 day moving average of $222.58 and a 200 day moving average of $212.26.

Laboratory Co. of America (NYSE:LH - Get Free Report) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $3.50 EPS for the quarter, beating analysts' consensus estimates of $3.48 by $0.02. Laboratory Co. of America had a return on equity of 15.39% and a net margin of 3.60%. The business had revenue of $3.28 billion for the quarter, compared to the consensus estimate of $3.26 billion. During the same quarter in the prior year, the business posted $3.38 EPS. The business's revenue for the quarter was up 7.4% on a year-over-year basis. Analysts predict that Laboratory Co. of America Holdings will post 14.55 EPS for the current fiscal year.

Laboratory Co. of America Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 13th. Investors of record on Tuesday, November 26th will be given a $0.72 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $2.88 dividend on an annualized basis and a yield of 1.26%. Laboratory Co. of America's dividend payout ratio (DPR) is 54.55%.

Institutional Trading of Laboratory Co. of America

Institutional investors have recently modified their holdings of the business. Industrial Alliance Investment Management Inc. acquired a new stake in shares of Laboratory Co. of America during the second quarter worth $27,000. Horizon Bancorp Inc. IN purchased a new position in Laboratory Co. of America in the 3rd quarter valued at about $29,000. Pathway Financial Advisers LLC acquired a new stake in Laboratory Co. of America during the 1st quarter valued at approximately $30,000. Innealta Capital LLC bought a new stake in shares of Laboratory Co. of America in the second quarter worth $32,000. Finally, Family Firm Inc. acquired a new stake in shares of Laboratory Co. of America in the 2nd quarter valued at about $37,000. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Evercore ISI decreased their price objective on shares of Laboratory Co. of America from $250.00 to $240.00 and set an "in-line" rating for the company in a report on Tuesday, September 24th. Barclays upped their price objective on Laboratory Co. of America from $234.00 to $249.00 and gave the company an "equal weight" rating in a research report on Friday. Robert W. Baird lifted their price objective on Laboratory Co. of America from $282.00 to $289.00 and gave the company an "outperform" rating in a research report on Friday. Piper Sandler started coverage on shares of Laboratory Co. of America in a report on Tuesday, October 1st. They set a "neutral" rating and a $235.00 price objective for the company. Finally, Jefferies Financial Group raised their target price on shares of Laboratory Co. of America from $245.00 to $265.00 and gave the company a "buy" rating in a report on Monday, September 23rd. Four research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $253.54.

About Laboratory Co. of America

Labcorp Holdings Inc provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests.